Paper Details

  1. Home
  2. Paper Details

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.

Author: ChaoJingdong, D'HaensGeert R, FeaganBrian G, LoftusEdward V, LomaxKathleen G, MulaniParvez, PanaccioneRemo, RutgeertsPaul J, SandbornWilliam J, SchreiberStefan, WuEric Q, YuAndrew P

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Adalimumab maintenance treatment in patients with moderate-to-severe Crohn's disease (CD) significantly reduced the risks of hospitalization and surgery compared to placebo.
Paper Details　
Original Abstract of the Article :
BACKGROUND & AIMS: We determined the effects of adalimumab maintenance treatment on the risks of hospitalization and surgery in Crohn's disease (CD). METHODS: A total of 778 patients with CD were randomized to placebo, adalimumab 40 mg every other week or adalimumab 40 mg weekly, all after an 80-mg...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1053/j.gastro.2008.07.069

データ提供：米国国立医学図書館（NLM）

Adalimumab: A Potential Oasis in the Desert of Crohn's Disease

Crohn's disease, a chronic inflammatory bowel disease, is a challenging condition for those who experience it. Researchers are constantly seeking new treatments to alleviate its symptoms and improve quality of life. This study focused on the effectiveness of adalimumab, a medication that targets a specific protein involved in inflammation, in managing Crohn's disease. The researchers recruited 778 individuals with Crohn's disease and randomly assigned them to receive either a placebo or adalimumab at different dosages. They then monitored the participants for hospitalizations and surgeries related to Crohn's disease over a year.

Adalimumab's Promise: A Beacon of Hope for Crohn's Patients

The results were encouraging. Patients receiving adalimumab experienced significantly lower hospitalization rates and fewer surgeries compared to those receiving a placebo. This suggests that adalimumab is a valuable tool in managing Crohn's disease, offering the potential for improved quality of life. The study showed a significant reduction in hospitalizations, with 52% to 64% fewer hospitalizations in the adalimumab groups compared to the placebo group.

Living with Crohn's Disease: Finding a Path to Wellness

For those grappling with Crohn's disease, this research brings a glimmer of hope. Adalimumab has shown promise in reducing hospitalizations and surgeries, offering a potential path to better health and well-being. While it's important to remember that individual responses to medications can vary, this study provides valuable insights into the potential benefits of adalimumab for managing Crohn's disease.

Dr.Camel's Conclusion

This study is like a desert oasis, offering relief and hope to those living with Crohn's disease. Adalimumab, a medication targeting inflammation, has shown promise in reducing the frequency of hospitalizations and surgeries. This research paves the way for a brighter future for individuals with Crohn's disease, giving them hope for a better quality of life.

Date :
  1. Date Completed 2008-11-25
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

18848553

DOI: Digital Object Identifier

10.1053/j.gastro.2008.07.069

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.